Randomized control trial of live Lactobacillus acidophilus plus Bifidobacterium infantis in treatment of infantile acute watery diarrhea.

OBJECTIVE: To evaluate the effectiveness of live Lactobacillus acidophilus plus Bifidobacterium infantis in the treatment of acute watery diarrhea. DESIGN: Open, randomized control trial. SETTING: King Chulalongkorn Memorial Hospital, Bangkok, Thailand. MATERIAL AND METHOD: Seventy-one infants (aged 1-24 months) with acute watery diarrhea that presented at Department of Pediatrics, King Chulalongkorn Memorial Hospital, Bangkok were enrolled after parental signed informed consent. They were randomized into 2 groups. The Study group (n = 35) received live Lactobacillus plus Bifidobacterium (3 x 10(9) CFU) bid and ORS and the Control group (n = 36) received ORS only. All infants received lactose free milk. Case record forms were completed daily for 5 days by the parents. RESULTS: All 71 infants completed the present study. There was no difference of the patients'characteristics and baseline clinical symptoms between the study group and the control group. Live Lactobacillus plus Bifidobacterium shortened the diarrhea duration (1.6 +/- 0.7 days vs 2.9 +/- 1.7 days, p < 0.01) compared to controls. However the stool frequency and duration of hospitalization were not significantly different (p > 0.05, study group vs control group). CONCLUSION: Live Lactobacillus acidophilus plus Bifidobacterium infantis may be an effective treatment for acute watery diarrhea in infants. The 2-day course treatment can significantly shorten the duration of diarrhea.

The prevalence of varicella-zoster virus infection in normal healthy individuals aged above 6 months.

The prevalence of varicella-zoster virus (VZV) infection was studied by determining the presence of IgG antibody to VZV (anti-VZV IgG) using ELISA method. Three hundred and fifty sera collected from Thai healthy individuals aged above 6 months (mean age +/- standard deviation = 14.9 +/- 11.4) were tested, the prevalence of VZV infection was 64.6% (225/350). All samples were randomly sampling from healthy children and blood donors who visited the hospital and clssified into 7 groups, 50 samples each, according to their age, i.e., group 1; 6 months-3 years, group 2; 4-6 years, group 3; 7-9 years, group 4; 10-14 years, group 5; 15-19 years, group 6; 20-24 years and group 7; above 25 years. The prevalence of VZV infection were 12%, 42%, 64%, 70%, 78%, 84% and 100% respectively. The mean amount of anti-VZV IgG among groups of positive VZV infection (225 samples) was 86.8 +/- 29.7 unit/ml. The mean amount of anti-VZV IgG was highest in 6 months-3 years age group (113.6 +/- 39.2 unit/ml). Significant difference of the mean amount of anti- VZV IgG was found between group 1, 3, 6 and other groups (p-value < 0.05). There was a correlation between history of varicella and the presence of anti-VZV IgG in the serum. 95.3% of individuals with positive history has already had the antibody. The important associated factors that might involve VZV infection were age, number of members in family and place of exposure to VZV infection. Other factors, such as sex and income did not show any association to VZV infection.

Prevalence of parvovirus B19 infection in Thai young adults.

The prevalence of antibody to human parvovirus B19 in 128 Thai healthy young adults was measured. Antibodies of the immunoglobulin G (IgG) class were investigated in serum samples of 51 males and 77 females aged 18-24 years (mean 19.83; SD 1.07) by a commercial enzyme-linked immunosorbent assay (ELISA) using high specific recombinant parvovirus B 19 antigen. Only 14 out of 128 (10.94%) sera were found positive, including 6 males and 8 females. No sex preponderance was observed. The amount of antibody calculated as antibody index was not statistically significant difference between genders.